However, the 2024 ESMO data from the ATHENA‐COMBO trial indicated that for ovarian cancer patients, the combination of the PARP inhibitor rucaparib and the PD‐1 inhibitor nivolumab showed inferior efficacy compared with rucaparib monotherapy, likely due to treatment discontinuation caused by severe adverse events [135]. Here, PDCD1 is linked to ovarian cancer.